The primary objective of this research project is to compare the effect of pharmacist interventions versus usual care in the implementation of guideline directed lipid lowering therapies for secondary prevention.
Studies have shown prevention of cardiovascular adverse events is directly proportional to percent reduction in low-density lipoprotein (LDL). This evidence explains why LDL targets for secondary prevention have continued to be lowered. Cholesterol guidelines have been updated recently and encourage the use of multiple lipid lowering therapies, in addition to statins, for secondary prevention. However, these novel agents can be expensive and difficult to acquire, making prescribing challenging for providers.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE
Enrollment
80
Pharmacist intervention may include but is not limited to prescribing (statins, ezetimibe, bempedoic acid, PCSK9 inhibitors, etc.), patient education, and medication access.
Atrium Health Cabarrus
Concord, North Carolina, United States
Number of Subjects Who Meet Low-density Lipoprotein (LDL) at Goal (<55)
patients with LDL within goal (\<55) (yes/no)
Time frame: Month 5
Percent Change in Low-density Lipoprotein (LDL)
Percent LDL reduction (will use baseline LDL and lowest LDL)
Time frame: Baseline to end of study period up to Month 5
Number of Participants With Medications Initiated or Titrated
Number of Medications initiated or titrated
Time frame: Baseline to end of study period up to Month 5
Prevalence of Elevated Lipoprotein(a)
Number of Subjects with Prevalence of elevated Lipoprotein(a)
Time frame: Baseline to end of study period up to Month 5
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.